BTIG lowered the firm’s price target on NeoGenomics (NEO) to $17 from $18 and keeps a Buy rating on the shares. Q4 results came in light “at an unfortunate time” following the “still surprising” news last month that the company’s turnaround specialist and CEO, Chris Smith, will leave both the CEO role and the board, the analyst tells investors. With that being said, the fundamentals of NeoGenomics core business today are “sound,” the analyst tells investors.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NEO:
- NeoGenomics price target lowered to $19 from $20 at TD Cowen
- NeoGenomics price target lowered to $16 from $19 at BofA
- NeoGenomics Achieves Double-Digit Revenue Growth in 2024
- NeoGenomics Q4 Earnings Call Highlights Growth Amid Challenges
- NeoGenomics: Overcoming Short-term Setbacks with Strategic Growth Initiatives and Leadership Transition